Brent Furse, CEO and President
Brent Furse has served as a Director and our Chief Executive Officer and President since June 2016. Prior to coming to Vero Biotech, Mr. Furse was a key member of the The Medicines Company leadership team where he joined in 2000 pre-IPO and served as a section 16 Officer. He held various leadership positions including Executive Vice President, Chief Operating Officer, Chief Commercial Officer, Vice President and General Manager Interventional Medicine, Vice President Surgery and Perioperative Care, and Vice President of Sales and Marketing. He was responsible for the launch and success of their flagship product Angiomax, and countless successful partnerships and operational excellence. In addition to his success at The Medicines Company, Brent has held leadership positions with Centers for Disease Control, Bristol-Myers Squibb, and Schering Plough Corporation, and serves on the board of Anthera Pharmaceuticals, The Special Olympics and Salus Tele-health.
Vinzenz Ploerer is President and CEO of Brace Pharma Capital. He is a Life Science executive with 30 plus years of extensive leadership experience in operations, acquisitions, and business development. Prior to launching Brace, Vinzenz worked at EMS S/A as Senior Vice President of Strategy and Operations. Mr. Ploerer has held various leadership positions at Novartis/Sandoz including Country Head of Brazil, Argentina, and Head of BDL Sandoz, building the company through acquisitions. Mr. Ploerer currently sits on several corporate boards including Vero Biotech, Therabron, Tyrogenex, and Navitor.
Todd Brady currently serves as the Director of Finance and Investments at Brace Pharma Capital. Mr. Brady also serves as a director for Brace portfolio companies, Vero Biotech, and Tyrogenex, as well as a board observer for Avidity Nanomedicines and Miragen Therapeutics. Mr. Brady has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Mr. Brady has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).
Daniel E Salazar, PhD
Dr Salazar is an accomplished pharmaceutical research and development executive with significant accomplishments across all phases of development and different therapeutic areas. His core areas of expertise are in translational science, clinical development, clinical pharmacology, pharmacokinetics, biopharmaceutics, pharmacometrics molecular pharmacology, pharmacogenomics, outsourcing, regulatory strategy, biomarkers, companion diagnostics and digital health. He has more than 25 years of experience in drug discovery, development, regulatory submissions and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs including Abilify®, Benicar HCT®, Azor®, Tribenzor®, Welchol®, Effient® and Sayvasa®. He is currently, Chief Scientific Officer and a member of the Board of Director of EMS Pharma, the leading pharmaceutical company in Brazil and Latin America. Dr Salazar is also Vice President Clinical and Regulatory, Brace Pharma Capital, the venture capital company of EMS Pharma located in Rockville, MD. Dr Salazar is the Acting Chief Technical Officer and a member of the Board of Managers for Vero Biotech. He also is Acting Sr Vice President of Development and Director for Tyrogenex, Inc. Dr Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo. He has directed over 100 clinical studies investigating dosage form bioequivalence, drug absorption, first administration to man, proof of concept, pharmacokinetics, pharmacodynamics, disease state interactions and drug-drug interactions. Dr Salazar is the co-author of 5 book chapters and 80 articles in peer reviewed journals.